⚠ This supplier name appears truncated — the Office of Government Procurement bulk file
contains shortened names for some legacy-platform rows. Cross-check before citing.
Lane I
Solo awards
€750k
awarded across 1 sole-awardee contract
The only credibly per-supplier-attributable money in this dossier — eTenders names a single awardee.
Lane II
Framework participations
0
multi-supplier frameworks · ceiling exposure €0
Per-supplier earnings cannot be derived — call-off splits between co-suppliers aren't in the source data. Read the count, not the money.
Lobbying register
32 matches
1 May, 2021 to 31 Aug, 2021
· Lobbyist: Mylan
1 Jan, 2021 to 30 Apr, 2021
· Lobbyist: Mylan
1 Sep, 2020 to 31 Dec, 2020
· Lobbyist: Mylan
1 Jan, 2020 to 30 Apr, 2020
· Lobbyist: Mylan
1 May, 2020 to 31 Aug, 2020
· Lobbyist: Mylan
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan welcoming pioneering HSE's new HIV Prevention Programme etc.
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan has a long-standing commitment to addressing unmet patient needs and leading the way when it comes to industry change. That’s why Mylan works in good faith with various stakeholders and uses strong alliances with industry associations. By doing so, we’re able to facilitate
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan has a long-standing commitment to addressing unmet patient needs and leading the way when it comes to industry change. That’s why Mylan works in good faith with various stakeholders and uses strong alliances with industry associations. By doing so, we’re able to facilitate
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan welcoming pioneering HSE's new HIV Prevention Programme etc.
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan welcoming pioneering HSE's new HIV Prevention Programme etc.
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Congratulations on election to the European Parliament & request to meet.
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan welcoming pioneering HSE's new HIV Prevention Programme etc.
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan has a long-standing commitment to addressing unmet patient needs and leading the way when it comes to industry change. That’s why Mylan works in good faith with various stakeholders and uses strong alliances with industry associations. By doing so, we’re able to facilitate
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
SPC Manafacturing Waiver proposals in the European Parliament / Commission.
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Mylan has a long-standing commitment to addressing unmet patient needs and leading the way when it comes to industry change. That’s why Mylan works in good faith with various stakeholders and uses strong alliances with industry associations. By doing so, we’re able to facilitate
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
Brexit; Ensuring the views of our Trade Association, Medicines for Ireland, and Mylan, were considered at high level meetings with Stakeholder group.
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Mylan
EU Pharmaceuticals in the Environment (PiE) Directive and related matters.
1 May, 2019 to 31 Aug, 2019
· Lobbyist: Mylan
Healthcare policy best practice in Europe, and market developments in Ireland and Brussels.
1 Jan, 2019 to 30 Apr, 2019
· Lobbyist: Mylan
Healthcare policy developments in Ireland and Brussels
1 Jan, 2019 to 30 Apr, 2019
· Lobbyist: Mylan
improve health and business policy
1 May, 2018 to 31 Aug, 2018
· Lobbyist: Mylan
Engaging to share best policy practice in order to improve patient access to medicines in Ireland, and a stronger more sustainable and competitive industry
1 Sep, 2018 to 31 Dec, 2018
· Lobbyist: Mylan
Mylan, Medicines for Ireland and Medicines for Europe are committed to supporting industrial policy initiatives aimed at strengthening the European industrial base, increasing investments in R&D for generic, biosimilar and value added medicines, boosting EU competitiveness, and t
1 Jan, 2018 to 30 Apr, 2018
· Lobbyist: Mylan
1 Sep, 2017 to 31 Dec, 2017
· Lobbyist: Mylan
Raise awareness of public health challenges of severe allergies and anaphylaxis.
1 Sep, 2017 to 31 Dec, 2017
· Lobbyist: Mylan
The Department of Health must develop and implement a National Biosimilars Policy, whose objective is to significantly increase the usage of biosimilars in Ireland . This policy must include: • Legislation which reforms the 2013 Act and allows for biosimilars to be included on th
7 additional matches not shown.
Top authorities
01St James's Hospital1
Spend areas
01Pharmaceutical products.1
Solo awards
1 record
Sole-awardee contracts. Awarded values reflect actual money paid to this supplier.
Date
Authority
Contract
Procedure
Estimated
Awarded
2018-03-15
St James's Hospital
TENDER (OJEU) FOR THE PROVISION, SUPPLY, SUPPORT AND DELIVERY OF ABACAVIR 600MG/LAMIVUDINE 300MG, ST. JAMES’S HOSPITAL 2018.
TEDCAN
Open Procedure
€800k
€750k
Framework participations
0 records
No multi-supplier framework participations on record.